8/8/2007 - Targeted Genetics said it was “premature as well as irresponsible” to draw any conclusions on what caused the death of a patient who participated in a clinical trial testing the safety of the firm’s new gene therapy.The biotech company was reacting to an article published in the Washington Post on Monday which alleged that the way the recruitment of the patient, who died on 24 July, was conducted was in serious breach of clinical trial regulation standards.
